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Background: Newer generation everolimus-eluting stents have improved angiographic and clinical outcomes compared with first-generation 
paclitaxel-eluting stents. However, it remains unclear whether there are differences in the safety and efficacy between everolimus-eluting and 
sirolimus-eluting stents in daily clinical practice.
Methods: We evaluated 3084 patients treated with everolimus-eluting stents and 3085 patients treated with sirolimus-eluting stents in 2008 and 
2009, using data from the Interventional Cardiology Research Incooperation Society-Drug-Eluting Stents Registry, including 55 cardiac centers. The 
primary end point was the incidence of major adverse cardiac events (MACE) at 12 -months, defined as a composite of death, nonfatal myocardial 
infarction, or target-vessel revascularization. The rates of adverse outcomes are adjusted by means of Cox proportional-hazards methods ad 
propensity-score analysis to account for differences in patients’ severity of illness, angiographic, and procedural characteristics.
Results: By multivariable Cox-regression analysis, there was no overall difference between the group that received everolimus-eluting stents and 
the group that received sirolimus-eluting stents in the primary end point of MACE (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.59-1.13, 
P=0.22) during 1 years of follow-up. However, the individual end point of death was significantly lower in the everolimus-eluting stents group than in 
the sirolimus-eluting stent group (HR, 0.54; 95% CI, 0.31-0.92, P=0.03). The rate of stent thrombosis did not significantly differ between 2 groups 
(HR, 0.72; 95% CI, 0.25-2.12, P=0.55). Overall findings were consistent even in the propensity analyses (matching and covariate adjustment).
Conclusions: In this large-scale, multi-center observational cohort in “real-world” PCI patients, everolimus-eluting stent resulted in similar rates of 
MACE compared with sirolimus-eluting stent during 1-year follow-up.
